The market for diabetes two-drug combination drugs that combine DPP-4 inhibitors and SGLT-2 inhibitors appears to be growing slowly despite the expansion of combination benefits at the beginning of the year. Since last May, two-ingredient combination drugs have appeared on the market one after another, but the cumulative prescriptions for related products in the five months until last September amounted to only 3.6 billion won.

The pharmaceutical industry is paying attention to the possibility that the market will expand, focusing on generic drugs, as the combination drug of dapagliflozin + sitagliptin has been released since the Januvia patent expired in September. The cumulative prescription amount f